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Lethal mutagenesis is the mechanism of action of ribavirin against poliovirus (PV) and numerous other RNA
viruses. However, there is still considerable debate regarding the mechanism of action of ribavirin against a
variety of RNA viruses. Here we show by using T7 RNA polymerase-mediated production of PV genomic RNA,
PV polymerase-catalyzed primer extension, and cell-free PV synthesis that a pyrimidine ribonucleoside
triphosphate analogue (rPTP) with ambiguous base-pairing capacity is an efficient mutagen of the PV genome.
The in vitro incorporation properties of rPTP are superior to ribavirin triphosphate. We observed a log-linear
relationship between virus titer reduction and the number of rPMP molecules incorporated. A PV genome
encoding a high-fidelity polymerase was more sensitive to rPMP incorporation, consistent with diminished
mutational robustness of high-fidelity PV. The nucleoside (rP) did not exhibit antiviral activity in cell culture,
owing to the inability of rP to be converted to rPMP by cellular nucleotide kinases. rP was also a poor substrate
for herpes simplex virus thymidine kinase. The block to nucleoside phosphorylation could be bypassed by
treatment with the P nucleobase, which exhibited both antiviral activity and mutagenesis, presumably a
reflection of rP nucleotide formation by a nucleotide salvage pathway. These studies provide additional support
for lethal mutagenesis as an antiviral strategy, suggest that rPMP prodrugs may be highly efficacious antiviral
agents, and provide a new tool to determine the sensitivity of RNA virus genomes to mutagenesis as well as
interrogation of the impact of mutational load on the population dynamics of these viruses.
Viruses with RNA genomes are the causative agents of nu-
merous infectious diseases of clinical relevance, and some are
considered significant threats as agents of bioterrorism. With
the exception of drugs targeting human immunodeficiency vi-
rus, few therapeutics exist for the treatment of RNA virus
infection. Thus, the development of broad-spectrum antiviral
treatments for RNA virus infections remains a crucial medical
research goal.
In the past several years, a number of studies have appeared
that support the use of lethal mutagenesis as a general antiviral
strategy (reviewed in reference 14). RNA viruses replicate with
a high error frequency due to the lack of proofreading activity
in the virus-encoded polymerases (11, 50). The resulting het-
erogeneous virus population has often been termed a quasi-
species (12). Quasispecies theory predicts the existence of an
error threshold, an upper limit to the mutation frequency be-
yond which genome viability is severely compromised. In one
study, poliovirus (PV) viability was reduced 99.3% when the
mutation frequency was increased only 9.7-fold beyond the
normal level (6). Thus, lethal mutagenesis is an antiviral strat-
egy which aims to increase the mutation rate of RNA viruses
beyond the threshold where virus viability can be maintained.
The antiviral nucleoside analogue ribavirin has been dem-
onstrated to act via lethal mutagenesis in vitro against a variety
of RNA viruses, including poliovirus (7), hepatitis C virus (28,
60), GB virus B (27), Hantaan virus (48), food-and-mouth
disease virus (1), and West Nile virus (9). Furthermore, other
antiviral nucleoside and nucleobase analogues have been pro-
posed to act via lethal mutagenesis, most notably 5-hydroxy-
2-deoxycytidine against human immunodeficiency virus (30),
5-azacytidine against foot-and-mouth disease virus (49), and
5-fluorouracil against poliovirus and vesicular stomatitis virus
(24), lymphocytic choriomeningitis virus (16, 46), and foot-
and-mouth disease virus (41, 42, 49).
However, there is still debate regarding the capacity for
ribavirin to act as a lethal mutagen, particularly whether direct
incorporation of a mutagen into viral RNA (vRNA) is suffi-
cient for antiviral activity. Ribavirin has been shown to act via
a number of different mechanisms, all of which may contribute
to its antiviral activity (reviewed in reference 15).
In addition, the applicability of quasispecies theory, error
catastrophe, and lethal mutagenesis concepts to viral evolution
has been controversial (10, 25, 26, 38). An important theoret-
ical advance was made by Schuster and Swetina in proposing
“survival of the flattest” (47). Using digital organisms, Wilke et
al. demonstrated that for populations evolving at high muta-
tion rates, high-fitness organisms could be outcompeted by
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lower-fitness organisms if the latter existed in a “flatter” region
of the fitness landscape (59). That is, populations subjected to
high mutation rates will evolve to exist in “flat” regions of the
fitness landscape where the density of neutral mutations is
high. This has become known as “mutational robustness” (54).
Whereas lethal mutagenesis and “survival of the flattest”
have been described theoretically and in digital models (58,
59), there has been little advance in these theories from an in
vitro or in vivo perspective. The interplay between mutational
load, polymerase fidelity, and mutational robustness is largely
unexplored. One approach to evaluating these theories in live
virus populations is by manipulating population error frequen-
cies through the use of mutagenic nucleoside analogues.
We have previously investigated the use of “universal” bases
with minimal hydrogen bonding potential as lethal mutagens of
PV (17, 19). Here we investigate the antiviral and mutagenic
potential of a nucleoside analogue with the capacity to stably
base pair with two natural nucleobases. The ribonucleoside
analogue 6-(-D-ribofuranosyl)-3,4-dihydro-8H-pyrimido[4,5-
c][1,2]oxazin-7-one (hereafter referred to as rP) (Fig. 1) is a
pyrimidine analogue with degenerate hydrogen-bonding prop-
erties (51). Tautomerization of the nucleobase (named P) al-
lows for two distinct configurations of hydrogen bond donors
and acceptors, permitting stable base pairing with either ade-
nine or guanine (Fig. 1).
Previous work with the ribonucleoside analogue (rP) and
related 2-deoxyribonucleoside analogue (dP) has established
that they can be utilized as substrates by multiple RNA and
DNA polymerases (22, 35, 52), and incorporation of rP into a
biologically active RNA molecule had little effect on its struc-
ture or activity (35). Furthermore, dP was shown to induce the
predicted transition mutations in Escherichia coli after phos-
phorylation through the bacterial thymidine kinase (TK) path-
way (40). dP has also been shown to induce C-to-U and U-to-C
transition mutations at a high rate in an in vitro retroviral
replication model (36). Templates containing rPMP were also
able to direct incorporation of either G or A by human immu-
nodeficiency virus and avian myeloblastosis virus reverse trans-
criptases (52). Accordingly, rP is considered to be an ambigu-
ous pyrimidine nucleoside analogue with high potential to
induce mutagenesis if utilized as a substrate by RNA virus
polymerases during genome replication. Herein, we evaluated
the abilities of rP and rPTP to function as lethal mutagens of
poliovirus.
We find that incorporation of rP into PV genomes synthe-
sized in vitro results in substantial loss of RNA specific infec-
tivity, indicating that incorporation of a mutagenic nucleotide
into viral RNA is sufficient to reduce virus fitness. Further-
more, rPTP is a highly efficient and promiscuous substrate for
the PV-encoded RNA-dependent RNA polymerase (RNAP)
3Dpol. Unfortunately, rP does not have antiviral activity in cell
culture, due to insufficient accumulation of the active triphos-
phate, although treatment with the nucleobase (P) demon-
strated mild antiviral activity and mutagenesis. In addition, a
poliovirus variant with a high-fidelity polymerase (G64S) dem-
onstrated increased sensitivity to direct incorporation of this
nucleotide into transcribed genomes. Direct incorporation of
rP into viral RNA genomes can therefore be used to elucidate
the effect of mutation frequency on the infectivity of viral
genomes and dynamics of the resulting virus population inde-
pendent of the error rate of the cognate polymerase or the
ability of the polymerase to incorporate the analogue.
MATERIALS AND METHODS
Cells and viruses. HeLa S3 cells (obtained from ATCC) were maintained in
Dulbecco’s modified Eagle’s medium (DMEM)/F-12 medium supplemented
with 2% dialyzed fetal bovine serum, 50 U/ml penicillin, and 50 g/ml strepto-
mycin (Invitrogen). Cells were maintained at 37°C in a 5% CO2 atmosphere.
Antiviral activity assays were performed as previously described (19). A guani-
dine resistance assay was performed as previously described (7). Statistical anal-
ysis was performed using Prism 4 for Windows (GraphPad Software, Inc.).
PV-WT and PV-G64S virus stocks were generated by transfecting HeLa cells
with full-length genomic RNA transcribed using T7 RNA polymerase from a
plasmid containing the viral cDNA (pMoRA or pMoRA-G64S) as previously
described (21, 56). Recovered virus was passaged a minimum of five times in
HeLa cells to allow for diversification of the virus population from the initial
cDNA sequence.
Expression and purification of T7 RNAP. T7 RNAP was purified as previously
described for PV 3Dpol (13) with the following modifications: (i) ammonium
sulfate was added to 40% saturation; (ii) the phosphocellulose column was
eluted using a linear gradient (six column volumes) from 50 mM to 700 mM NaCl
in buffer A; (iii) the Q-Sepharose column was loaded and washed and the protein
eluted using a linear gradient (six column volumes) from 50 mM to 400 mM NaCl
in buffer A. Protein-containing fractions were pooled as before. Additional steps
to concentrate the protein were not necessary.
Incorporation of RTP by T7 RNA polymerase. Incorporation by T7 RNAP
opposite templating bases cytosine or thymine in assembled enzyme-primer/
template complexes was examined for ribavirin triphosphate (RTP) and the
correct natural nucleotide (GTP opposite cytosine, ATP opposite thymine).
Assay conditions were modified from those described in reference 53. The RNA
primer sequence was 5-UUUUGCCGCGCC-3. The DNA template sequence
providing templating C (underlined) was 5-GGGAATGTACGGCGCGGC-3.
The DNA template sequence providing templating T (underlined) was 5-GGG
AATGCATGGCGCGGC-3. RNA primer was 5-end labeled with [-32P]ATP
by using T4 polynucleotide kinase according to the manufacturer’s protocol
(New England BioLabs). Annealing of 32P-end-labeled RNA primer with DNA
template was accomplished by heating to 90°C for 1 min followed by cooling to
10°C at a rate of 5°C per min. T7 RNAP was allowed to preassemble with the
primer/template duplex for 10 min at room temperature immediately prior to
reactions. Reactions were at 30°C for 30 or 180 s in 50 mM HEPES pH 7.5, 10
mM 2-mercaptoethanol, and 5 mM MgCl2 with 2 M T7 RNAP, 1 M primer/
template duplex, and 0.5 mM RTP or natural nucleotide. Reactions were initi-
ated by addition of nucleotide and terminated by quenching in 100 mM EDTA–
90% formamide gel loading dye. Reaction products were separated by
denaturing polyacrylamide gel electrophoresis (PAGE), and gels were visualized
using a Typhoon 8600 variable mode imager (Molecular Dynamics) as previously
described (13).
In vitro transcription by T7 RNA polymerase. A plasmid containing the PV
genomic cDNA under the control of a T7 promoter (pMoRA) (21) was linear-
ized via digestion with the restriction enzyme ApaI (New England BioLabs). The
transcription reaction mixture contained 350 mM HEPES (pH 7.5), 32 mM
magnesium acetate, 40 mM dithiothreitol, 2 mM spermidine, 7 mM each nucle-
oside triphosphate (ATP, CTP, GTP, and UTP), 0.5 g linearized plasmid DNA,
and 0.5 g purified T7 RNA polymerase in a final volume of 0.02 ml. rPTP was
added at various concentrations with an equimolar amount of magnesium ace-
tate. The mixture was incubated for 3 h at 37°C followed by a 2-min centrifuga-
FIG. 1. P base pairs with adenine and guanine. P exists as two tau-
tomers: imino-P and amino-P. The former hydrogen bonds with adenine;
the latter hydrogen bonds with guanine. The imino-P/amino-P ratio is
approximately 11:1 (20).
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tion at 14,000  g. The pellet was discarded, and 2 U of RQ1 DNase (Promega)
was added to the supernatant, followed by incubation at 37°C for an additional
30 min to digest template DNA. RNA was precipitated by the addition of 0.05 ml
of 7.5 M lithium chloride with 50 mM EDTA. This mixture was frozen on dry ice
for 15 min and centrifuged at 14,000  g for 30 min at 4°C. The supernatant was
discarded, and the RNA pellet was washed twice with 70% ethanol, air dried, and
resuspended in deionized water. Quality of full-length genomic RNA was veri-
fied by agarose gel, and RNA was quantitated by fluorescence in the presence of
ethidium bromide by comparing to a known RNA standard.
Digestion of T7-transcribed RNA to component nucleosides. RNA digestion
was performed essentially as previously published (5). Briefly, RNA suspended in
20 l deionized water (approximately 2 g/l) was denatured at 100°C for 3
min and then rapidly chilled in an ice water slush. A 1/10 volume of 0.1 M
ammonium acetate (pH 5.3) was added, followed by addition of 2 U nuclease P1
(MP Biochemicals) and incubation for 2 h at 45°C. A 1/10 volume of 1 M
ammonium bicarbonate (pH 7.8) was then added to the digest, followed by 1 U
shrimp alkaline phosphatase (USB Corporation) and further incubation for 1 h
at 37°C. The solution was heated to 95°C for 10 min to inactivate enzymes prior
to high-performance liquid chromatography (HPLC) separation.
HPLC separation and detection method. HPLC separations were performed
on a Hewlett Packard (Agilent) 1100 series instrument equipped with an in-line
solvent degasser and diode array detector. RNA digests were separated on an
Aquasil C18 column (4.6 by 250 mm, 5 m; Keystone Scientific Inc., Thermo
Electron Corp.) and eluted with the following linear gradient (1-ml/min flow
rate): 1 to 95% acetonitrile in 100 mM monobasic potassium phosphate buffer
(KH2PO4, pH 6.0) over 15 min. The phosphate buffer was prepared by dissolving
KH2PO4 in distilled and deionized water (ddH2O) at 100 mM and adjusting the
pH to 6.0 by addition of 10% KOH (aqueous). Acetonitrile employed in the
separation was HPLC grade. The elution of ribonucleosides (cytidine, uridine,
adenosine, and guanosine) was detected at 254 nm; elution of rP was detected at
295 nm. Injection volumes for treatments ranged from 7.5 l to 15 l; the
injector port was fitted with a 20-l injection loop. Peak areas were obtained by
standard integration of the appropriate peak by the ChemStation for LC 3D
software (rev. A.09.03; Agilent Technologies).
Generation of standard stocks and fitting of data points. rP was dissolved in
ddH2O at a 2.5 mM concentration, and serial dilutions were prepared. Ribonu-
cleoside standards were prepared by serial dilution of 25 mM stocks of cytidine
and uridine (in ddH2O) and guanosine and adenosine (in dimethyl sulfoxide).
Individual analyses of a range of ribonucleoside concentrations were performed
for each standard, and the resulting peak areas were plotted against the quantity
of material injected (in nmoles). Linear regression analysis of the tabulated
calibration lines found an R2 of 0.99 for each of the standards.
Identification of peaks and tabulation of the abundance of P in transcribed
RNA. The identities of nucleosides from the RNA digestion were assigned by
doping the transcription mixture with known standards and observing an increase
in the area of the corresponding peak (compared with nondoped analyses). The
relative abundance of each nucleoside in the transcriptional mix was determined
by fitting the area of the separated peak to the corresponding standard line
formula. The percentage of rP in each RNA digestion was tabulated by dividing
the nanomoles of rP by the total nanomoles of nucleosides in the sample. Each
digestion was analyzed in triplicate, with the mean representing the average of
these individual analyses. As a control to ensure that residual rPTP was ade-
quately washed away from transcribed RNA, a control experiment was per-
formed in which transcription was performed with only the four natural nucle-
otides. After digestion of the DNA template and immediately prior to lithium
chloride precipitation, rPTP was added at the highest concentration used for
transcription. This RNA was precipitated, washed, and digested, and the nucleo-
sides were separated by HPLC as described above. No rP was detected in this
control experiment, indicating that unincorporated nucleotides were adequately
removed from the RNA solution prior to digestion and separation (data not
shown).
Transfection and infectious center assays. An infectious center assay to de-
termine the specific infectivity of transcribed PV genomic RNA was performed
as previously described (6). HeLa S3 cells were detached via treatment with
trypsin-EDTA (Invitrogen), washed with 1 phosphate-buffered saline (PBS),
and resuspended in 1 PBS at 3  106 cells/ml. The cell suspension (0.4 ml) was
mixed with 0 to 10 g T7-transcribed RNA and transferred to an electroporation
cuvette (0.2-mm gap; VWR International). Electroporation was performed using
a Gene Pulser (Bio-Rad) set at 500 F and 130 V. Electroporated cells were
serially diluted in 10-fold increments in PBS, and 0.1 ml of each dilution and the
undiluted electroporated cell suspension was plated onto a subconfluent HeLa
S3 monolayer plated the previous day at 5  105 cells/well in six-well plates
containing 1.5 ml of growth medium. Cells were incubated for 1 h at 37°C to
allow for attachment. Wells were aspirated, and the monolayers were covered
with 3 ml of DMEM/F-12 with 2% dialyzed fetal bovine serum and 1 penicillin-
streptomycin supplemented with 1% low-melting-point agarose (American Bio-
analytical). Plates were incubated for 3 days at 37°C before removal of the agar
plug and staining with 0.1% crystal violet solution in 20% ethanol for visualiza-
tion of plaques. For the experiments shown in Fig. 4B, below, data were nor-
malized such that for each individual experiment the number of plaques resulting
from RNA transcribed in the absence of rPTP was set to 100.
For the experiment comparing wild-type and G64S PV, RNA was transfected
as described above. Following electroporation, 0.2 ml of cell suspension was
added to 0.8 ml of growth medium and incubated in a 37°C water bath for 6 h.
The cell suspension was then subjected to three freeze-thaw cycles for cell lysis
and centrifugation for 2 min at 14,000  g to remove cellular debris. The
supernatant titer was determined on HeLa cell monolayers for 3 days followed by
staining with crystal violet solution.
Nucleotide incorporation by PV 3Dpol in vitro. PV 3Dpol was expressed and
purified as previously described (13). Extension assays utilizing symmetrical
primer/template substrates (s/s) were performed as described elsewhere (2). s/s
RNAs were synthesized by Dharmacon, Inc., and 5-end labeled with [-32P]ATP
by using T4 polynucleotide kinase according to the manufacturer’s protocol
(New England BioLabs). Annealing of 32P-end-labeled RNA primer to form the
duplex substrate was accomplished by heating to 90°C for 1 min followed by
cooling to 10°C at a rate of 5°C per min. 3Dpol was incubated with the appro-
priate s/s duplex for 90 s at 30°C to allow formation of preinitiation enzyme-RNA
complexes. Extension reactions were initiated by the addition of nucleotide and
incubated at 30°C for the indicated times. The initiated reaction mixture con-
tained 1 M 3Dpol, 1 M s/s (0.5 M duplex), 50 mM HEPES (pH 7.5), 10 mM
2-mercaptoethanol, 5 mM MgCl2, 60 M ZnCl2, and nucleoside triphosphate as
indicated for each experiment. Reactions were quenched by addition of EDTA
(pH 8.0) to 50 mM. Polymerase was diluted immediately prior to use in 50 mM
HEPES (pH 7.5), 10 mM 2-mercaptoethanol, 60 M ZnCl2, and 20% glycerol.
For all experiments, 100 M nonradiolabeled s/s “trap” was added along with
initiating nucleotide to prevent reinitiation of dissociated enzyme. Product was
added to an equal volume of loading buffer (90% formamide, 0.025% bromphe-
nol blue, and 0.025% xylene cyanol) and heated to 65°C prior to loading on a
denaturing polyacrylamide gel containing 23% acrylamide, 1 TBE (89 mM Tris
base, 89 mM boric acid, and 2 mM EDTA), and 7 M urea. Electrophoresis was
performed in 1 TBE at 80 W for 2 h. Products were visualized using a
Typhoon 8600 variable mode imager (Molecular Dynamics) as previously de-
scribed (13). Quantitation was performed using ImageQuant software (Molec-
ular Dynamics) and fit by nonlinear regression using KaleidaGraph 3.5 software
(Synergy Software, Reading, PA).
Thymidine kinase assay. Purified recombinant herpes simplex virus type 1
(HSV-1) TK and ganciclovir (GCV) were a gift of Richard R. Drake (Eastern
Virginia Medical School). Nucleoside substrates were assayed as described pre-
viously (23). The reaction mixture consisted of 0.01 to 1 mM nucleoside, 20 mM
potassium phosphate (pH 7.6), 1 mM dithiothreitol, 0.160 M ATP, 0.106 M
[	-32P]ATP (MP Biochemicals), 5 mM MgCl2, 25 mM NaF, 40 mM KCl, and 0.5
mg/ml bovine serum albumin. The mixture was incubated for 5 min at 37°C prior
to addition of purified HSV-1 TK to a final concentration of 3.85 g/ml. The
mixture was incubated at 37°C for 5 min and then quenched by addition of
EDTA (pH 8.0) to 80 mM. One l of the quenched reaction mixture was spotted
on polyethyleneimine-cellulose F thin-layer chromatography plates (EMD
Chemicals) and resolved with 300 mM potassium phosphate, pH 7.0. The thin-
layer chromatography plate was exposed to a phosphor screen (Molecular
Dynamics) for 30 min and visualized using a Typhoon 8600 variable mode
imager (Molecular Dynamics). Quantitation and curve fitting were performed
using ImageQuant 5.0 (Molecular Dynamics) and KaliedaGraph 3.5 (Synergy
Software).
Selection of a HeLa S3 cell line expressing HSV-1 TK. A mammalian expres-
sion plasmid containing the HSV-1 TK gene (pLTKEN) was provided by Rich-
ard R. Drake (Eastern Virginia Medical School) (32). HeLa S3 cells were
transfected with pLTKEN via lipofection with DMRIE-C reagent (Invitrogen)
according to the manufacturer’s protocol. Stably transfected cells were selected
in the presence of 0.4 mg/ml G418 sulfate (Invitrogen). After 2 weeks of selec-
tion, 12 colonies were isolated, expanded, and screened for sensitivity to 25 M
ganciclovir. Five clones demonstrating robust growth and sensitivity to ganciclo-
vir were then screened for HSV-1 TK expression by lysing cells (4  107 cells/ml)
in 1 cell culture lysis reagent (Promega). Total protein concentration was
determined by the Bradford assay (Bio-Rad Laboratories), and 15 g of protein
from each sample was separated via sodium dodecyl sulfate (SDS)-PAGE using
a 10% acrylamide gel followed by transfer to nitrocellulose. HSV-1 TK was
detected via Western blotting using rabbit HSV-1 TK polyclonal antiserum
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(provided by Margaret E. Black, Washington State University) and goat anti-
rabbit immunoglobulin G–horseradish peroxidase. The blot was developed using
Amersham ECL Western blotting detection reagents and exposed to X-ray film.
The clone showing the highest expression of HSV-1 TK (hereafter referred to as
HeLa-TK) was expanded and used exclusively for further experiments.
Nucleotide extraction from HeLa and HeLa-TK cells. Nucleotide extraction
was modified from a previously published procedure (45). A total of 7.5  106
HeLa S3 or HeLa-TK cells were plated in a 100-mm dish 15 to 18 h before
treatment. Cells were treated with 2.5 g/ml actinomycin D (Sigma) for 15 min
at 37°C, and then rP was added to the medium to a final concentration of 2 mM.
Cells were incubated for 3 h at 37°C. After incubation, the medium was aspi-
rated, plates were washed with 5 ml PBS, and 1 ml prewarmed trypsin-EDTA
solution (Invitrogen) was added to each plate. Cells were incubated for 5 min at
37°C to facilitate detachment, after which cells were collected, pelleted, and
resuspended in 0.05 ml ice-cold 0.6 M trichloroacetic acid (Sigma). The cell
suspension was incubated on ice for 10 min and then centrifuged at 14,000  g
for 2 min at 4°C. The supernatant was collected and extracted with an equal
volume of ice-cold 0.5 M trioctylamine in 1,1,2-trichlorotrifluoroethane (Sigma).
Samples were then vortexed for 30 s and centrifuged for 30 s at 14,000  g and
4°C. The upper (aqueous) layer was removed and analyzed on a Hewlett Packard
1100 series instrument equipped with an Aquasil C18 analytical column (4.6 by
250 mm, 5 m; Keystone Scientific Inc., Thermo Electron Corp.) running the
following mobile phase (flow rate, 1 ml/min): gradient of 1% to 15% CH3CN in
100 mM potassium phosphate buffer (KH2PO4, pH 6.0) over 20 min, followed by
15 to 80% CH3CN in 100 mM KH2PO4 buffer over 10 min.
Cells and viruses for cell-free translation and replication. HeLa R19 cell
monolayers and suspension cultures of HeLa S3 cells were maintained in DMEM
supplemented with 10% fetal bovine calf serum. Poliovirus for vRNA prepara-
tion was amplified on HeLa R19 cells as described previously (31). The infectivity
of virus stocks was determined by plaque assays on HeLa R19 monolayers, as
described previously (31).
Preparation of poliovirus vRNA. Virus stocks were grown and purified by CsCl
gradient centrifugation (31). Viral RNA was isolated from the purified virus
stocks with a 1:1 mixture of phenol and chloroform. The purified RNA was
precipitated by the addition of two volumes of ethanol.
Preparation of HeLa cytoplasmic extracts. HeLa S10 extracts were prepared
as previously described (8, 33) except for the following modifications: (i) packed
cells from 2 liters of HeLa S10 were resuspended in 1.0 volume (relative to
packed cell volume) of hypotonic buffer; (ii) the final extracts were not dialyzed.
Translation-RNA replication reactions with HeLa cell extracts and plaque
assays. Viral RNA was translated at 34°C in the presence of unlabeled methio-
nine, 200 M each of CTP, GTP, and UTP, and 1 mM ATP in a total volume of
25 l (8, 33). After incubation for 12 to 15 h, the samples were diluted with
phosphate-buffered saline and were added to HeLa cell monolayers. Virus titers
were determined by plaque assay, as described previously (31). A 1 mM concen-
tration of rPTP was added to the reaction mixture as indicated.
Translation-RNA replication reactions with HeLa cell extracts and in vitro
translation. Translation reaction mixtures (25 l) containing 8.8 Ci of
Trans35S-label (ICN Biochemicals) and vRNA were incubated for 12 h at 34°C
(8). A 1 mM concentration of rPTP was added to the reaction mixture as
indicated. The samples were analyzed by electrophoresis on SDS–12% poly-
acrylamide gels, followed by autoradiography.
Translation-RNA replication reactions with HeLa cell extracts and luciferase
assay. The P/L replicon (wild type) (29) was used to measure the luciferase
activity in translation-RNA replication reactions. The P/L replicon was linearized
with DraI (New England BioLabs) prior to transcription by T7 RNA polymerase.
The transcript RNA was purified by phenol-chloroform extraction and ethanol
precipitation. After the P/L replicon was translated for 12 h at 34°C in the
presence of unlabeled methionine, 200 M each of CTP, GTP, and UTP and 1
mM ATP in a total volume of 25 l (8, 33, 34), the total reaction mixture was
transferred to a tube. A 100-l aliquot of luciferase assay reagent (Promega) was
mixed with 25 l of lysate, and the firefly luciferase activity was measured in an
Optocomp I luminometer (MGM Instruments, Inc.). Puromycin (Sigma) was
added to the reaction mixture as indicated.
RESULTS
Incorporation of ribavirin triphosphate by T7 RNA poly-
merase. Lethal mutagenesis as the mechanism of action of
ribavirin could be supported by synthesizing PV genomic RNA
containing a known number of ribavirin monophosphate (RMP)
substitutions and evaluating the phenotype of virus popula-
tions produced from these RNAs. The synthesis of P is de-
scribed in supplemental material which can be found at (http:
//bmb.psu.edu/faculty/cameron/lab/JVI2007Supplement.html.).
We investigated the ability of T7 RNAP to utilize RTP as a
substrate by using a primer-extension assay. As shown in Fig. 2,
RTP was a poor substrate for T7 RNAP compared with the
correct nucleotides when either C or T was used as the first
templating base. Thus, poor incorporation of RTP by T7 RNA
polymerase precludes its incorporation into PV genomic RNA
in vitro at a frequency sufficient to reduce genome infectivity.
Incorporation of rP into PV genomic RNA in vitro. The
nucleotide analogue rPTP has been established as an ambigu-
ous substrate for T7 RNAP (35). To determine the effect of rP
incorporation into PV genomic RNA, rPTP was added along
with all four naturally occurring nucleotides during in vitro
transcription of the PV genome by T7 RNAP. No significant
reduction in the RNA yield by T7 transcription was observed
when rPTP was added at up to 20% of the total nucleotide
concentration, indicating that rPTP does not cause inhibition
of RNA synthesis or premature termination when utilized as a
substrate for T7 RNAP under these conditions (Fig. 3C).
To demonstrate incorporation of rPMP into transcribed
RNA, the RNA was precipitated by lithium chloride followed
by washing with 70% ethanol to remove residual nucleotides.
The RNA was then digested to its nucleoside constituents
using nuclease P1 and shrimp alkaline phosphatase. Nucleo-
side products were separated via reversed-phase HPLC and
detected by UV absorbance. A peak corresponding to rP could
be seen for RNA transcribed in the presence of PTP (Fig. 3A).
The identity of each peak was verified by doping the RNA
digest with standards of rP and all four naturally occurring
nucleosides (data not shown).
Quantitation of the rP peak in relation to the four naturally
occurring nucleoside peaks provided a measure of the incor-
poration of rPMP into RNA by T7 RNAP when various con-
centrations of rPTP were added to the in vitro transcription
reaction mixture. The rP content of RNA increased linearly
with increasing concentrations of rPTP available during tran-
FIG. 2. RTP is not an efficient substrate for T7 RNAP. (A) Sub-
strates used for the T7 RNAP extension assay are illustrated with
DNA template (top strand) and RNA primer (bottom strand). The
templating nucleotide is indicated in bold. (B) Primer extension by
T7 RNAP is shown after 30 and 180 seconds when either RTP or the
correct nucleotide was provided as substrate. RMP was incorpo-
rated inefficiently compared to the correct (natural) substrate. The
asterisk indicates an 11-mer extended RNA substrate.
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scription (Fig. 3B). When rPTP was added equimolar to each
of the four natural nucleotides (7 mM), 15% of the digested
RNA product consisted of rP.
Specific infectivity of PV genomic RNA containing rP. The
infectivity of PV genomic RNA containing rP was measured by
infectious center assay as previously described (6). PV genomic
RNA was transcribed as described above and transfected into
HeLa S3 cells by electroporation. Serial dilutions of trans-
fected cells were then added to subconfluent HeLa S3 mono-
layers and incubated under an agar overlay for 3 days. Repli-
cation-competent RNA genomes launch an authentic PV
infection upon transfection, resulting in virus spread and a
plaque in the cell monolayer. This allows for quantitation of
infectious RNA genomes.
To determine the concentrations of RNA that would result
in a linear response for plaque formation, various amounts of
T7 RNAP-transcribed PV genomic RNA were transfected into
HeLa cells (Fig. 4A). The number of productively infected
cells (as measured by subsequent plaque formation) was found
to be linear when up to 5 g of RNA was transfected. Three g
was used for all subsequent experiments.
PV genomic RNA was transcribed by T7 RNAP in the pres-
ence of various concentrations of rPTP. When this RNA was
transfected into HeLa S3 cells, an rPTP-dependent decrease in
RNA infectivity was observed (Fig. 4B). Specific infectivity was
defined as the number of plaques observed per g of RNA per
ml of transfected cells. Specific infectivity was normalized such
that the number of plaques resulting from transfection with
RNA containing no rPMP was set to 100. Data described
above for the amount of rP in RNA based on transcription
conditions (Fig. 3B) were extrapolated to estimate the number
of rPMP incorporations per genome required to provide a
given reduction in genome specific activity. Approximately 20
molecules of rPTP incorporated per genome (0.3% nucleo-
tide composition) were sufficient for a 10-fold reduction in
specific infectivity. Thus, the presence of rP in viral genomes
has a dramatic effect on the ability of those genomes to launch
productive infections.
Incorporation of rP into RNA by PV 3Dpol. To confirm that
rP acts as an ambiguous nucleoside during poliovirus repli-
cation, the ability of the PV RNA-dependent RNA poly-
merase (3Dpol) to utilize rPTP as a substrate was deter-
mined using an in vitro primer-extension assay. Symmetrical
primer/template substrates (s/s) were utilized as previously
described (2). Purified PV 3Dpol was mixed with RNA du-
plex primer/template for 90 s to allow for the formation of
stable elongation complexes, at which time nucleotide sub-
strate was added. The reaction was stopped at various times
FIG. 3. rPMP is incorporated into genomic RNA during transcription with T7 RNAP. (A) HPLC separation of RNA transcribed in the
presence of rPTP. RNA was digested to component nucleosides as described in the text. rP was observed along with the four natural nucleosides.
(B) rPMP composition of RNA (as determined by HPLC of digested RNA) is plotted against the concentration of rPTP present in the in vitro
transcription reaction mixture. The PV genome is 7.5 kb in length. (C) RNA transcribed in the presence of increasing concentrations of rPTP was
run on a 1% agarose gel and stained with ethidium bromide. Differences in RNA quality or length were not observed when rPTP was added to
the transcription reaction mixture at up to 20% of the total nucleotide pool. L, DNA ladder.
FIG. 4. rPMP incorporation into PV genomic RNA results in a
dose-dependent decrease in specific infectivity. (A) HeLa S3 cells were
transfected with various concentrations of in vitro-transcribed RNA
and serially diluted on HeLa S3 monolayers. Resulting plaques in-
creased linearly up to 5 g. (B) PV genomic RNA was transcribed in
vitro in the presence of various concentrations of rPTP, and infectivity
was determined in an infectious center assay. The number of rPMP
incorporations per genome is plotted on the x axis, as determined by
extrapolating the data in Fig. 3B for transcription in the presence of
various amounts of rPTP. Specific infectivity was normalized such that
for each experiment the number of plaques resulting from RNA tran-
scribed in the absence of rPTP was set to 100. The mean and standard
deviation of at least three independent samples are shown for each
data point.
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post-nucleotide addition, and product was separated by de-
naturing PAGE (Fig. 5). rPMP was efficiently incorporated
into RNA by 3Dpol when the templating base was either aden-
osine or guanosine. As indicated by the kpol/Kdapp, rPMP (from
the rPTP substrate) was incorporated into RNA by PV 3Dpol
approximately 100-fold more efficiently than incorporation of
the known mutagen ribavirin (Table 1). Furthermore, incor-
poration was equally efficient opposite either adenosine or
guanosine, confirming the promiscuous base-pairing properties
of rP (Fig. 6A). Incorporation was not detected when cytidine
or uridine was utilized as the templating base (data not shown).
Next, the ability of PV 3Dpol to further extend RNA having
rPMP at the terminal 3 position was evaluated. An extension
reaction using s/s-A was performed as described above, but
with ATP added to the reaction mixture along with rPTP.
AMP should be incorporated in the second templated position
immediately after incorporation of rPMP, resulting in quanti-
tative extension of the 10-mer s/s-A substrate to a 12-mer
product (Fig. 6B). AMP was found to be incorporated quan-
titatively as the 2 nucleotide, indicating that incorporation of
rPMP does not result in “chain termination” by preventing
further extension at the 3 end of the RNA. These experiments
suggest that rPTP can be templated efficiently by either cyti-
dine or uridine during poliovirus RNA replication and that
incorporation of rPMP should not result in premature termi-
nation of the nascent RNA.
Treatment of HeLa S3 cells with rP during PV infection. In
light of the observation that rPMP incorporation causes a
reduction in specific infectivity of PV genomic RNA, the an-
tiviral properties of rP were evaluated against PV in cell cul-
ture. HeLa S3 cells were pretreated with rP for 1 h and infected
with PV at a multiplicity of infection of 0.01 in order to max-
imize the cumulative effects of replication in the presence of a
mutagen. PV infection was allowed to proceed in the presence
of rP until all cells demonstrated cytopathic effect, at which
time virus was collected from the medium and the titer was
determined. Treatment of cells with up to 2 mM rP failed to
reduce the time required to reach cytopathic effect and did not
cause a reduction in virus titer (data not shown). Furthermore,
analysis of cellular nucleotide pools (as described below) failed
to detect any phosphorylated rP metabolites in extracts of
HeLa cells treated with 2 mM rP for 3 h (data not shown).
FIG. 5. PV polymerase incorporates rPMP opposite both adenine
and guanine in RNA. Either s/s-A (A) or s/s-G (B) was employed.
Utilization of rPTP was compared directly to utilization of the correct
nucleotide: UTP (A) or CTP (B). Polymerase-s/s complexes were
assembled and nucleotide added to a final concentration of 500 M.
Product formed after 15, 30, 45, 60, 120, 300, and 600 s was separated
from substrate by denaturing PAGE and visualized by phosphorimag-
ing. Extended RNA product is indicated by the asterisks.
FIG. 6. PV 3Dpol utilizes rPTP more efficiently than ribavirin
triphosphate. (A) Poliovirus polymerase 3Dpol was incubated with s/s
for 120 s prior to initiating the reaction by addition of the appropriate
nucleotide to a final concentration of 500 M. The solid and dashed
lines represent fits of the data to a single exponential with kobs of
0.30 
 0.02 s1 and 0.44 
 0.05 s1 for rPMP incorporation opposite
A (F) and G (f) and kobs of 0.008 
 0.001 s
1 and 0.009 
 0.004 s1
for rRMP incorporation across U (E) and C (), respectively. (B) A
chain termination experiment was performed with s/s-A as described in
the legend for Fig. 6A. Incorporation was monitored in the presence of
rPTP alone (left panel) or in the presence of rPTP and ATP, the next
correct nucleotide (right panel). Quantitative incorporation of AMP
was observed (the n  2 product is indicated by the asterisk).








GCUAGGGCCC UTPb 98 
 2 266 
 2 2.7
CCCGGGAUCG rPTP 134 
 48 0.47 
 0.05 0.0035
s/s-C
GAUCGGGCCC GTPb 3.8 
 0.7 57 
 3 15
CCCGGGCUAG RTPc 430 
 79 0.019 
 0.002 0.000044
s/s-G
CAUGCCCGGG CTPb 19 
 3 157 
 8 8.2
GGGCCCGUAC rPTP 132 
 29 0.59 
 0.05 0.0045
s/s-U
CGAUGGGCCC ATPb 134 
 18 86.7 
 3.7 0.86
CCCGGGUACG RTPc 496 
 21 0.014 
 0.001 0.000028
a The templating bases are underlined.
b Data are based on reference 3.
c Data are based on reference 7.
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rP is a substrate for HSV-1 thymidine kinase. The failure of
rP to exhibit antiviral activity could potentially be due to inef-
ficient phosphorylation of the nucleoside by cellular nucleoside
and nucleotide kinases, which would prevent accumulation of
the nucleoside triphosphate necessary for incorporation into
RNA. The rate-limiting step for intracellular accumulation of
a nucleoside triphosphate in cells is often the initial phosphor-
ylation that results in production of the nucleoside monophos-
phate (55). TK from HSV-1 is a nucleoside kinase with broad
substrate specificity (44). We examined the ability of HSV-1
TK to phosphorylate rP in vitro using purified HSV-1 TK. For
comparison, the natural substrate thymidine (T) and the anti-
herpesvirus nucleoside analogue GCV were evaluated in par-
allel. Steady-state kinetics produced the kinetic constants in
Table 2. The kcat/Km for rP was reduced 10-fold relative to that
for T and 3-fold relative to that for GCV, primarily due to an
increase in the Km. Nonetheless, HSV-1 TK is able to phos-
phorylate rP in vitro with an efficiency comparable to known in
vivo nucleoside substrates.
We reasoned that expression of HSV-1 TK in HeLa cells
may be sufficient for activation of rP, resulting in antiviral
activity due to lethal mutagenesis. To this end, we introduced
an HSV-1 TK expression plasmid conferring neomycin resis-
tance (32) into HeLa cells and selected stably transfected cells
by addition of 400 g/ml G418 sulfate to the culture medium.
Colonies were screened for sensitivity to GCV, and then a
Western blot assay was performed to assess the degree of
expression of HSV-1 TK (data not shown). The colony with the
most favorable expression, referred to as HeLa-TK, was ex-
panded and used for subsequent experiments.
Determination of intracellular phosphorylation states of rP
in HeLa-TK cells. To investigate the intracellular metabolism
of rP, HeLa-TK cells were treated with 2 mM rP for 3 h,
followed by nucleotide extraction and HPLC analysis of nucle-
otide pools as previously described (45). Cells were treated
with actinomycin D for 15 min prior to addition of rP to the
medium in order to prevent incorporation of phosphorylated
rP metabolites into cellular RNA. Phosphorylated forms of rP
were not detected by this method (Fig. 7). However, the un-
modified nucleoside was readily detected, indicating that the
absence of phosphorylated metabolites was not due solely to
exclusion of the nucleoside from the cytoplasmic compart-
ment. Furthermore, treatment with rP did not reduce the titer
of PV produced by infected HeLa-TK cells (data not shown).
P exhibits mild antiviral activity and mutagenesis of PV.
Treatment of HeLa cells with rP did not result in detectable
levels of rPTP in cells and did not exhibit any observable
antiviral effect or increased mutagenesis of PV genomes. This
may be due to the inability of rP to be phosphorylated through
the cellular de novo nucleotide metabolism pathways. How-
ever, administration of the nucleobase (P) might allow metab-
olism via the cellular nucleotide salvage enzymes, resulting in
accumulation of the active triphosphate to sufficient intracel-
lular levels. To explore this possibility, we treated HeLa S3
cells with P at concentrations of up to 2 mM. No overt cellular
toxicity was observed by visual inspection through 3 days of
continuous exposure to the nucleobase at these concentrations
(data not shown).
P was tested for antiviral activity against PV under one-step
growth conditions. HeLa S3 cells were pretreated with P for 1
hour prior to infection with PV (MOI, 5). Fresh P in medium
was then added prior to incubation for 6 h at 37°C, followed by
collection of cell-associated virus and determination of virus
titer. A mild decrease in titer was observed, approximately
twofold with treatment with 0.5 mM or higher (Fig. 8A).
To probe the mechanism responsible for this antiviral activ-
ity, the mutation frequencies of the resulting virus populations
were estimated using a previously established assay for guani-
dine resistance (7). Poliovirus replication is completely inhib-
ited in the presence of 3 mM guanidine hydrochloride, but a
single transition mutation is sufficient to restore viability.
Hence, measurement of the frequency of guanidine-resistant
PV variants can be used as an estimate of mutation frequency.
When PV, grown in the presence of various concentrations of
P, was assayed in this manner, a mild increase (twofold) in
guanidine-resistant variants was detected (Fig. 8B). However,
FIG. 7. rPTP is not detected in HeLa-TK cells treated with rP.
(A) Separation of extracts from untreated HeLa-TK cells (100-l
injection). (B) Separation of extracts from HeLa-TK cells that were
treated with 2 mM rP for 3 h (100-l injection). rP (retention time [tR],
11.8 min) was clearly observed in treated extracts. No new peaks with
rPTP retention (tR, 2.2 min) or characteristic UV trace were observed.
The absorbance wavelength for all traces was 295 nm.
TABLE 2. Steady-state kinetic constants of HSV-1 thymidine kinasea
Nucleoside or
analogue Km (M) kcat (10
3 s1) kcat/Km (M1 s1)
T 1.7 
 1.1 3.5 
 0.3 2,100
GCV 7.8 
 2.9 4.0 
 0.3 510
rP 29 
 9.1 5.5 
 0.6 190
a Values are means 
 standard deviations.
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this increase was not statistically significant when analyzed by
analysis of variance (P  0.05) (37).
Antiviral activity of rPTP in a PV cell-free replication sys-
tem. To examine the effects of rPTP on poliovirus infection, we
utilized a well-established cell-free replication system employ-
ing HeLa cell extracts (33). When programmed with PV
genomic RNA, translation, replication, and production of in-
fectious virus particles can be observed in these extracts. Ad-
dition of 1 mM rPTP to the cell-free translation reaction mix-
ture resulted in no reduction in translation of replicon RNA as
monitored by luciferase production, whereas addition of the
translation inhibitor puromycin caused a complete block of
luciferase production (Fig. 9A). Furthermore, no detectable
effect on the processing of the PV polyprotein was observed in
the presence of rPTP (Fig. 9B). However, infectious virus
production in the presence of rPTP was reduced approxi-
mately 80-fold (Fig. 9C). Because the presence of rPTP
itself does not inhibit cell-free translation of the input RNA,
the decreased infectivity of virus synthesized in cell extracts
containing rPTP reflects a posttranslational effect.
rPTP substitution causes a replication defect in the polio-
virus subgenomic replicon. To determine whether incorpo-
rated rPMP can affect virus replication, a poliovirus sub-
genomic replicon, wherein the capsid coding region is replaced
by a luciferase reporter (21), was transcribed in the presence of
rPTP as previously described (18). Reporter activity was mon-
itored following transfection into HeLa S3 cells. When RNA
containing approximately 16.5 substitutions per genome was
transfected, translation of input RNA was reduced approxi-
mately 50% as determined by incubation in the presence of 3
mM guanidine hydrochloride, a poliovirus replication inhibitor
(Fig. 10A). Translation was further diminished as additional
rPMP substitutions were made (Fig. 10B). While this may
reflect translational effects due to erroneous codon recognition
of rPMP-containing RNA, it also likely reflects at least some
loss of functionality due to mutation of the luciferase coding
region induced by rPMP incorporation.
rPMP-substituted RNA was transfected into HeLa cells and
monitored for reporter activity over 8 h (Fig. 10A). Genomes
containing an average of 16.5 substitutions per genome exhib-
ited diminished replication kinetics and an approximately 15-
fold reduction in reporter activity at 8 h. Genomes containing
an average of 1,155 substitutions per genome exhibited no
reporter activity in the presence or absence of 3 mM guanidine
hydrochloride.
A high-fidelity PV variant has increased sensitivity to rPTP
incorporation. The preceding experiments suggest that incor-
poration of rPMP is deleterious to the PV genome through
increased mutagenesis of the virus genomic sequence. A high-
fidelity PV (G64S) variant was previously identified as resistant
to ribavirin treatment due to a twofold increase in fidelity of
the virus-encoded RNA-dependent RNA polymerase (4, 43).
If decreased infectivity of rPTP-containing genomes were due
to increased mutagenesis, a high-fidelity variant would be less
likely to “correct” those mutations during subsequent rounds
of replication, resulting in an increased rate of fixation of
deleterious mutations. Therefore, the high-fidelity G64S vari-
ant should be more sensitive to mutations introduced into the
genome by T7 RNAP-mediated transcription.
We tested this hypothesis by transcribing both wild-type and
FIG. 8. P exhibits mild antiviral and mutagenic properties.
(A) HeLa cells were pretreated for 1 hour with P and then infected
with PV (MOI, 5), followed by a 6-h incubation at 37°C. Cell-associ-
ated virus was recovered by freeze-thaw, and the titer was determined.
Experiments were performed in triplicate. (B) A guanidine resistance
assay was performed in triplicate as described in the text.
FIG. 9. Cell-free translation of PV genomic RNA is unaffected by
the presence of rPTP. (A) Cell-free reactions were programmed with
PV replicon RNA containing luciferase in place of the capsid-coding
sequence. Translation was measured after 12 h via a luciferase activity
assay. (B) Cell-free reactions were programmed with PV vRNA. After
12 h of translation, products were separated via SDS-PAGE. (C) Ex-
tracts were programmed with PV vRNA, and viable virus produced
was quantitated by plaque assay.
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high-fidelity (G64S) PV genomes in the presence of various
concentrations of rPTP. These RNA genomes were transfected
into HeLa cells via electroporation, and the transfected cells
were added to growth medium and incubated for 6 h at 37°C to
allow for virus amplification over one replicative cycle. Result-
ant virus population titers were determined on HeLa mono-
layers. The G64S variant showed increased sensitivity to rPTP
genomic substitution (Fig. 11). At approximately 33 substitu-
tions per genome, the G64S virus titer was reduced 20-fold
compared to wild-type virus under the same conditions.
DISCUSSION
Lethal mutagenesis as an antiviral strategy remains contro-
versial, primarily due to the fact that mutagenesis alone has not
been directly demonstrated to be sufficient for antiviral activity
in vitro or in vivo. Known nucleoside analogues, including
ribavirin, generally have multiple pathways through which they
can exert antiviral activity, including polymerase inhibition and
perturbation of cellular nucleotide pools through interaction
with the enzymes of nucleotide metabolism. In addition, riba-
virin and other purine analogues must compete with relatively
large intracellular purine pools to act as effective mutagens.
Here we have demonstrated that mutagenesis of viral genomic
RNA itself is sufficient for substantial reductions in virus in-
fectivity. While the nucleoside analogue evaluated herein did
not exhibit antiviral activity in cell culture, we have directly
demonstrated the application of lethal mutagenesis as an an-
tiviral strategy, as well as the potential of nucleobase analogues
with tautomeric constants near unity to act as lethal mutagens
when used as substrates for RNA-dependent RNA poly-
merases. Further research in the area of tautomeric nucleo-
bases should lead to analogues that are effective in vivo.
Previous work has shown that rP and dP can be incorporated
promiscuously by a number of RNA and DNA polymerases,
respectively. We demonstrated that rP is also recognized as an
ambiguous pyrimidine analogue by a virus-encoded RNA-de-
pendent RNA polymerase (PV 3Dpol). Crotty and colleagues
observed a 3.2-fold reduction in RNA specific infectivity when
ribavirin-treated poliovirus genomic RNA was found to have
1.9 mutations per genome through sequencing of capsid coding
regions (6). Here, we show approximately 16 incorporations of
rPMP are required for an equivalent reduction in RNA specific
infectivity. This apparent discrepancy may be reconciled by
noting that every incorporation event will not result in a mu-
tation. Furthermore, the tautomerization of P (KT of approx-
imately 11) favors the imino form (mimicking uridine) (20).
Accordingly, T7 RNA polymerase demonstrates a marked
preference for recognition of rPTP as a uridine analogue (35).
Mutational assays in E. coli (40) and an in vitro retroviral
replication model (36) both showed a bias towards C-to-U (or
T) mutations over U- (or T)-to-C by nearly a factor of 2,
consistent with the imino form of P as the most thermodynam-
ically favorable conformation.
The loss of RNA infectivity when rPMP is incorporated into
RNA may be due to a number of factors. P is an ambiguously
hydrogen-bonding base, and its incorporation into genomic
RNA should result in transition mutations. Thus, increased
mutation of the coding sequence caused by genomic incorpo-
ration of rPMP may elicit loss of protein function, including
the generation of dominant negative mutations. Secondly, the
FIG. 10. The PV replicon containing rPMP shows a reduction in
active luciferase reporter activity. The PV replicon contains the lucif-
erase reporter in place of the capsid-coding sequence. Replicons were
transcribed under conditions previously shown to result in 0, 16.5, 33,
or 82.5 rPMP substitutions per RNA molecule. (A) Replicon-trans-
fected cells were incubated in the presence (open symbols) or absence
(closed symbols) of 3 mM guanidine hydrochloride for 8 h. (B) Rep-
licon-transfected cells were incubated for up to 3 h in the presence of
3 mM guanidine hydrochloride. Activity of the luciferase reporter was
reduced by a maximum of 10-fold.
FIG. 11. rPMP substitution in genomic RNA is more deleterious to
a high-fidelity PV variant (G64S). Cells were transfected by T7 RNAP-
transcribed RNA containing a known number of rPMP substitutions,
followed by incubation at 37°C for 6 h. Cell-associated virus was col-
lected by freeze-thaw, and the titer was determined. Titers were nor-
malized such that the titer of virus produced by RNA with no rPMP
substitutions was set to 100. The titer resulting from transfection of
wild-type (WT) genomes containing no PTP was 2.3 106 PFU/ml; for
G64S, the titer was 6.6 106 PFU/ml.
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unconventional structure of rP may preclude its recognition as
part of a codon during RNA translation. The presence of
unnatural bases may also affect the stability of the RNA ge-
nome, resulting in more rapid degradation of the RNA in the
cellular milieu. This can impact the infectivity of the genome if
the effective lifetime of the molecule is too short to allow a
productive infection to be established. Finally, the presence of
P may affect the ability of the RNA to form secondary and
tertiary structures required for translation and virus replica-
tion. Thus, mutation may affect not only the primary (protein
coding) sequence of the virus but also the higher-order struc-
tures that are known to play essential roles during the virus life
cycle as well as in genome stability.
Inefficient phosphorylation of rP by cellular nucleotide and
nucleoside kinases likely explains the lack of antiviral activity
of this nucleoside in cell culture. Experiments performed with
standards of the nucleoside indicated a lower limit of detection
of approximately 1 nmol under the HPLC conditions employed
(data not shown). Based on the extraction conditions, this
would allow detection of intracellular P metabolites present at
approximately 20 M or higher. Our failure to detect any
metabolites other than the ribonucleoside indicate that, even if
rP were recognized as a substrate for intracellular kinases,
phosphorylated forms would not accumulate to high levels.
Additionally, the ability to detect the nucleoside (rP) at sub-
stantial levels indicates that the lack of activity is likely not due
to degradation or metabolism of the nucleoside, or failure of
the nucleoside to accumulate intracellularly. While our studies
with the nucleobase (P) did demonstrate antiviral activity and
mutagenesis (albeit statistically insignificant), this does not
necessarily mean that rPTP accumulates intracellularly after
treatment with the nucleobase. The nucleobase itself could
have other activities which caused the observed mutagenic
effect, such as perturbation of cellular nucleotide pools
through interaction with the nucleotide biosynthetic enzymes
of the cell.
The failure to detect intracellular phosphorylated metabo-
lites of rP highlights an important complication of nucleoside-
based antiviral therapy, as relatively high levels of metaboli-
cally downstream nucleotides may need to be achieved for
sufficient antiviral activity. Mutagenic nucleoside analogues are
prodrugs in that they must be activated by cellular enzymes
(nucleoside and nucleotide kinases) in order for the active
(triphosphorylated) form to accumulate. The specificity of cel-
lular nucleoside, nucleotidyl, and nucleoside diphosphate
kinases is therefore a crucial factor in the activity of nucleo-
side-based therapeutics. A pronucleotide approach could po-
tentially be utilized in delivering rPMP (or even rPTP) to cells,
protecting the charged phosphates to allow cellular entry and
liberation of the phosphorylated form in the cytoplasm by
cellular metabolic enzymes (reviewed in reference 57). How-
ever, it is still unknown if available rPMP in the cytoplasm of
mammalian cells will lead to accumulation of the triphosphor-
ylated form (rPTP) and observable antiviral activity. Given the
high capacity for mutagenesis exhibited by P, a prodrug of rP
containing masked 5 phosphates has the potential for signif-
icant antiviral activity.
Lethal mutagenesis was proposed as an antiviral strategy
almost 15 years ago. Despite this, previous attempts to design
novel mutagenic nucleotide analogues that are capable of in-
ducing mutation in RNA viruses have had only limited success
(17–19, 39). In this study, we have demonstrated that rPTP is
an efficient and ambiguous substrate of a viral RNA-depen-
dent RNA polymerase. rPTP was incorporated 100-fold more
efficiently than the known mutagenic nucleoside ribavirin in
vitro. P therefore represents an important lead compound for
the development of clinically useful antiviral therapies based
on lethal mutagenesis of RNA virus genomes.
Direct mutagenesis of viral RNA through T7-mediated tran-
scription as described herein also holds potential for unravel-
ing the sensitivity of RNA viruses to mutagenesis outside of the
context of the virus-encoded polymerase. A number of posi-
tive-sense RNA viruses have genomes that can be manipulated
in vitro to examine the effects of mutational load on population
fitness. As such, this study introduces a potential methodology
to screen for viruses that may exhibit enhanced sensitivity to
lethal mutagens due to low mutational robustness. It may also
be used as a tool to understand the interplay between poly-
merase fidelity, infectivity, genome conservation, and virus
evolution.
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